Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung: Final analysis of the randomised phase 3 LUX-Lung 8 trial

BACKGROUND: LUX-Lung 8 was a randomised, controlled, phase 3 study comparing afatinib and erlotinib as second-line treatment of patients with advanced squamous cell carcinoma (SCC) of the lung. We report the final overall survival (OS) and safety analyses of LUX-Lung 8 and investigate the characteri...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:EClinicalMedicine
Main Authors: Goss, Glenwood D, Cobo, Manuel, Lu, Shun, Syrigos, Konstantinos, Lee, Ki Hyeong, Göker, Erdem, Georgoulias, Vassilis, Isla, Dolores, Morabito, Alessandro, Min, Young J, Ardizzoni, Andrea, Bender, Shaun, Cseh, Agnieszka, Felip, Enriqueta
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier 2021
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8225678/
https://ncbi.nlm.nih.gov/pubmed/34195574
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.eclinm.2021.100940
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados